Death receptor-based enrichment of Cas9-expressing cells by Liesche, Clarissa et al.
RESEARCH ARTICLE Open Access
Death receptor-based enrichment of Cas9-
expressing cells
C. Liesche1, L. Venkatraman1, S. Aschenbrenner1, S. Grosse2, D. Grimm2, R. Eils1* and J. Beaudouin1
Abstract
Background: The CRISPR/Cas9 genome editing system has greatly facilitated and expanded our capacity to
engineer mammalian genomes, including targeted gene knock-outs. However, the phenotyping of the knock-out
effect requires a high DNA editing efficiency.
Results: Here, we report a user-friendly strategy based on the extrinsic apoptosis pathway that allows enrichment
of a polyclonal gene-edited cell population, by selecting Cas9-transfected cells that co-express dominant-negative
mutants of death receptors. The extrinsic apoptosis pathway can be triggered in many mammalian cell types, and
ligands are easy to produce, do not require purification and kill much faster than the state-of-the-art selection drug
puromycin. Stringent assessment of our advanced selection strategy via Sanger sequencing, T7 endonuclease I (T7E1)
assay and direct phenotyping confirmed a strong and rapid enrichment of Cas9-expressing cell populations, in some
cases reaching up to 100 % within one hour. Notably, the efficiency of target DNA cleavage in these enriched cells
reached high levels that exceeded the reliable range of the T7E1 assay, a conclusion that can be generalized for editing
efficiencies above 30 %. Moreover, our data emphasize that the insertion and deletion pattern induced by a specific
gRNA is reproducible across different cell lines.
Conclusions: The workflow and the findings reported here should streamline a wide array of future low- or
high-throughput gene knock-out screens, and should largely improve data interpretation from CRISPR experiments.
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Background
The CRISPR/Cas9-system has become an extremely
powerful tool for the editing of genes in various cell
types. The method was born thanks to the study of clus-
tered, regularly interspaced, short palindromic repeat
(CRISPR)-genes and CRISPR-associated (Cas) genes of
bacteria, which constitute part of the bacterial defense
mechanism [1, 2]. As a tool in molecular and cell biology,
the CRISPR/Cas9-system is employed by co-expressing a
single guide RNA (gRNA), which targets a DNA sequence
of interest, and the Cas9 nuclease, which can bind to the
gRNA and produce double-strand breaks [3–6]. Repeated
cycles of cut and faulty repair by the cellular non-
homologous end joining machinery can eventually generate
insertion/deletion (indel) mutations, and consequently a
knock-out effect in cases where these mutations introduce
a frame-shift within the targeted gene.
By targeting DNA, the CRISPR/Cas9 system perfectly
complements gene knock-down on the RNA level by
RNA interference for the annotation of gene functions
[7]. Importantly, as compared to siRNA/shRNA technol-
ogy, phenotyping by gene knock-out is not constrained
by a reduction of gene expression that can be incom-
plete and that can vary from cell to cell. From this per-
spective, the technique will be particularly useful to
screen for gene functions. CRISPR/Cas9-based screens
have so far used pooled libraries, in situations where the
identification of hits was allowed by the isolation of cells
showing the right phenotype [8–12]. Arrayed screens
can offer a broader range of phenotyping possibilities
[13] which can go up to subtle changes at the cellular
scale that can only be observed by microscopy. There-
fore, combining the pipelines existing for arrayed RNAi
screens [14] and the CRISPR/Cas9technology should
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provide a highly sensitive tool to determine gene func-
tions. Still, a technical limitation of the CRISPR/Cas9-
system is the efficiency of gene knock-out within a cell
population, which remains a limiting and highly variable
factor. For example, the first studies validating the
CRISPR approach for mammalian cells demonstrated
proportions of gene-edited cellular subpopulations ran-
ging between 2 and 25 %, depending on the cell type
and the mode of Cas9/gRNA transfection [3, 6, 15]. Two
main strategies have improved the efficiency, the first
being the optimization of the delivery method, using e.g.
lentiviral, adenoviral or Adeno-associated viral (AAV)
vectors [16]. Lentivirus libraries have successfully been
used for various screening projects [8–12] and AAVs
have been applied in animals [17–19]. Potential draw-
backs of this viral vector strategy are the requirement to
work under elevated biosafety levels (lenti- and adenovi-
ruses), the stable chromosomal integration of the viral
genomes encoding the Cas9 nuclease (lentiviruses), or
the limited capacity for packaging of foreign DNA such
as Cas9 cDNAs (AAV). The other strategy consists of
selecting, enriching and expanding cells from a cell
population by using co-expressing markers [20], as
briefly summarized in the following. Co-expression of
fluorescent proteins [21, 22] or of reporter plasmids
exhibiting fluorescent protein expression after editing of
the reporter gene [23, 24] allows for easy and robust se-
lection by flow cytometry sorting. Nevertheless, its appli-
cation in arrayed screens would be laborious. Another
selection strategy that is more amenable for a screening
strategy consists of killing cells that are not expressing
Cas9. This was performed either by co-expressing Cas9
and a gene that provides resistance to a drug [20, 25, 26]
or by co-editing a gene of interest and a gene that would
induce cell death upon treatment with a drug. This last
approach was performed by targeting the HPRT gene
and by using 6-TG as death inducer [27]. The fluores-
cence- and drug-based approaches have the advantage of
relying on transient expression of Cas9, and therefore
can be considered as scarless: the only genome modifica-
tion that is left after the transient expression is the edit-
ing event itself, but no Cas9/gRNA insertion or acquired
drug resistance. Regarding the selection by cell killing,
the process should occur within two days, during the
typical peak of expression of the resistance gene. For this
reason, puromycin is typically preferred to other drugs
as it generally kills cells within 24 to 48 h. Provided a
good balance between killing of non-transfected cells
and survival of transfected cells, one can yield efficient
genome editing even in the case of suboptimal transfec-
tion with limited cost and material.
Here, we aimed at enlarging the panel of tools for
potent and fast enrichment of gene-edited cells, and thus
implemented an original strategy based on killing of
transfected cells that lack Cas9 expression through the
extrinsic apoptosis signaling pathway. The activation of
the TNF receptor family members FAS/CD95 by CD95
ligand (CD95L), or DR4 and DR5 by TRAIL, can induce
cell death in many cellular contexts through the activa-
tion of caspases [28–30]. This activation occurs through
the recruitment of the adaptor protein FADD on the
death domain (DD) of oligomerized, ligand-associated
receptors [31]. Because of this oligomerization step,
receptor mutants that lack the DD can block apoptosis
even in the presence of wild type (wt) receptors, in a
dominant-negative manner [32]. We therefore hypothe-
sized that co-expression of the Cas9 nuclease with such
receptor mutants would render cells resistant to CD95L-
or TRAIL-induced apoptosis, and that incubation with
the appropriate ligand would allow for the enrichment
of Cas9-positive cells with no further modification of the
cells. In vitro, killing cells can be efficiently achieved by
using modified forms of soluble CD95 and TRAIL
ligands that are, for example, fused to an isoleucine
zipper [33]. Ligands can be produced in-house in a
straightforward and inexpensive manner, do not require
purification and kill cells within a few hours.
For proof-of-concept, we successfully applied our
method to the p65 subunit of NFκB, IRF3 and TLR3,
using three different gRNAs per gene. By using the T7E1
assay and Sanger sequencing, we obtained estimations of
up to 100 % gene-edited cells. As a result of this enrich-
ment, we could directly show the involvement of the three
genes in Poly (I:C)-induced cell death in HeLa cells. More-
over, we observed that a given gRNA generated a reprodu-
cible indel pattern in different cell lines. This pattern
showed a limited complexity, which had a strong influence
on the calculation of editing efficiency from the T7E1
assay. We conclude that our strategy extends the panel of
tools for the CRISPR/Cas9 technology and can be particu-
larly applicable to screens as it is easy to implement and
reduces the time for the selection of gene-edited cells.
Results
Death receptor-based selection of Cas9-expressing cells
We established a death receptor-based selection system
that enriches Cas9-expressing cells in order to generate
polyclonal, gene-edited cell populations. To this end, we
designed a single plasmid encoding gRNA and Cas9
nuclease together with the selection gene that is co-
expressed via a 2A peptide, adapted from [10] (Fig. 1a).
Using death ligands as selection agent, we aimed at killing
non-transfected cells and cells expressing too low levels of
Cas9 nuclease. As selection genes, we used truncations of
death receptors that are unable to transmit the apoptotic
signal (see workflow on Fig. 1b). More precisely, we made
truncated receptors missing their death domain (ΔDD) for
the death ligand CD95 ligand (CD95-ΔDD) or TRAIL
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Fig. 1 Constructs and workflow of death receptor-based enrichment of Cas9-expressing cells. a Constructs for different selection strategies. The
Cas9 nuclease is linked to the resistance gene by a cleavable 2A peptide allowing stoichiometric expression. As resistance gene, we used death
receptors that lack the intracellular death domain, denoted by Δ. CD95 is chosen when using CD95L as selection agent. DR4 and DR5 are death
receptors that bind the death ligand TRAIL. To allow simultaneous expression of several death receptors, we linked them to Cas9 via the 2A peptide from
Thosea asigna virus (T2A), from foot-and-mouth disease virus (F2A) and porcine teschovirus-1 (P2A). To allow comparison to the puromycin selection strategy,
we cloned the puromycin resistance gene puromycin N-acetyl-transferase, denoted here as puro. We used the human cytomegalovirus (CMV) and the 7SK
promoters for the protein and gRNA expression, respectively. b Workflow. Cells are transfected with a plasmid encoding the Cas9 nuclease, a selection
gene and the gRNA. Two days after transfection, death ligand was added to the cells, before they were washed and expanded
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(DR4-ΔDD and DR5-ΔDD) (Fig. 1a). We tested their
single expression as well as the simultaneous expression
of both, DR4-ΔDD and DR5-ΔDD, or even of all three
mutant receptors, CD95-ΔDD, DR4-ΔDD and DR5-ΔDD,
from the same construct. As detected by immunofluores-
cence, all our vectors robustly over-expressed the mutant
receptors in the different cell lines that were tested, HeLa,
HT-1080, LN-18 and MDA-MB-231 (Additional file 1:
Figure S1-S4).
As we aimed at developing a strategy that would
minimize the requirements for production of reagents,
we next tested the possibility to directly use secreted,
non-purified ligands expressed in HEK 293 T cells. We
measured the apoptotic activity of soluble death ligands
(sCD95L and sTRAIL) that are fused to the isoleucine-
zippper domain (IZ), denoted as IZsCD95L and IZs-
TRAIL, in different human cell lines (including those
from Additional file 1: Figure S1-S4): HeLa, HT-1080,
LN-18, MDA-MB-231, HepG2, MCF10A and A549
(Fig. 2a and b). With the exception of A549, all cell lines
showed more than 99 % cell death within 5 h with at
least one of the ligands. Remarkably, 1 h was even suffi-
cient to kill HeLa and HepG2 cells. Addition of 5 or
50 μg/μl cycloheximide, known to amplify the sensitivity
to death receptors [34], could further enhance cell death
in some cases. Still, in all cells except A549, one of the
two ligands efficiently induced cell death without cy-
cloheximide (Fig. 2), showing that those ligands can be
directly used as strong selection agent. Notably, cell
death induced by puromycin, even at saturating con-
centrations, required about 30 hours to kill more than
99 % HeLa, LN-18 and MDA-MB-231 cells (Fig. 2c
and S5). Therefore, cell death can be more efficiently
induced by death ligands than by puromycin.
Estimating genome editing efficiency in HeLa cells by
Sanger sequencing and T7E1 assay
In order to test the capacity of our death receptor strat-
egy to efficiently generate gene-edited cells, we targeted
three different genes in HeLa cells, IRF3, TLR3 and p65,
with three different gRNAs for each gene. As CD95L
killed HeLa cells more efficiently than TRAIL (Fig. 2a),
we used the Cas9-2a-CD95ΔDD construct. As mock
control, we used a gRNA that was designed to target gfp
(see Table 1 for the primer and gRNA sequences used in
this study). Two days after transfection, cells were incu-
bated for 5 h with IZsCD95L. We also kept cells trans-
fected with TLR3 gRNA-1 untreated, denoted as TLR3
gRNA-1*. Seven days after treatment, genomic DNA was
extracted for analysis and the remaining cells were kept
in culture for direct phenotyping. We evaluated the
editing efficiency, denoting the fraction of mutant DNA
species, by using two different methods, namely the
analysis of Sanger sequence chromatograms (Fig. 3a)
and the T7E1 assay (Fig. 3b). To quantify the mutations
from sequencing chromatograms, we applied the TIDE
(Tracking of Indels by DEcomposition) analysis, a se-
quence decomposition approach [35]. To this end, we
PCR-amplified the genomic region targeted by the differ-
ent gRNAs in the polyclonal HeLa cell lines. The three
gRNAs for one gene were located in the same region of
the genome, hence we used the same primers for each
gene. To check the consistency of the indel calculation,
we sequenced each PCR product from both sides of the
cut (Table 1). In all cases, sequencing chromatograms
already provided a clear visual impression of the pres-
ence of genetic modifications, mostly evidenced by a
unique sequence before the cutting site and a mixture of
sequences behind it (Additional file 1: Figure S6). In
some cases, a small amount of mutated sequences was
also detected before this cutting site, which likely corre-
sponds to large indels that start after the sequencing pri-
mer (see arrows in Additional file 1: Figure S6).
Strikingly, in cell lines enriched for IRF3 and p65 cleav-
age, no wt sequence of the respective genes was detected
(Fig. 3a), while the amount of wt TLR3 sequence was 8
to 36 %. In contrast, no indels were identified in non-
enriched TLR3 gRNA-1* cells or in enriched gfp gRNA
control cells (Fig. 3a, TLR3 gRNA-1 inset and upper
plots). Therefore, this first approach indicated efficient
enrichment of gene-edited cells. Interestingly, the muta-
tion pattern was different for each tested gRNA and
appeared to be of limited complexity, with a total of 4 to
11 indels for each gRNA (Fig. 3a and S7). This number
may reflect a detection limit of the sequencing/TIDE
approach. Nevertheless, as evidenced by the ranked
frequency of indels, in most cases few indels represented
the highest proportion of mutations (Additional file 1:
Figure S7).
Using the T7E1 assay, we obtained fractions of cleaved
PCR product (cleaved/[cleaved + noncleaved]) ranging
between 77 and 90 % (Fig. 3b and c, yellow bars). In
contrast to the sequencing results, cells that were not
treated with IZsCD95L still showed 41 % cleavage. The
editing efficiency is typically calculated from the fraction
of cleaved PCR products as follows [36]:
editing efficiency ¼ 1−
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1−fractioncleaved
p
ð1Þ
Following this estimation, we obtained editing efficien-
cies ranging between 53 and 70 % for cells treated with
IZsCD95L and 23 % for non-selected cells (Fig. 3d).
Thus, both approaches verified successful editing and
enrichment of cells. Yet, they showed a large discrepancy
in the editing efficiency for enriched cells, reaching up
to 100 % for the sequencing approach versus up to 70 %
for the T7E1 approach. In contrast, non-enriched cells
showed 0 % editing by sequencing but 23 % by the T7E1
Liesche et al. BMC Biotechnology  (2016) 16:17 Page 4 of 13
approach (Fig. 3d, TLR3 gRNA-1*). These discrepancies
led us to revisit the estimation of the editing efficiency.
On the one hand, the Sanger sequencing might not be
sensitive enough to detect a low fraction of mutant
DNA species in the non-enriched sample, and vice versa,
to detect a low amount of wt sequences in the enriched
samples. On the other hand, the editing efficiency calcu-
lated using equation (1) relies on the assumption that
the diversity of mutated strands is sufficiently large so
that those mutated strands never reanneal with strands
carrying the same mutation [36]. In other terms, only
the wt strands would form homoduplexes and would
remain uncleaved by the endonuclease. As we identified
a low diversity of indels by sequencing, this questioned
the validity of the aforementioned assumption. In order
to test it, we calculated the expected cleavage fraction in
an endonuclease assay by assuming that not only wt but
also mutant homoduplexes can form. As explained in
the Additional file 1: Supplemental note, this can be
expressed as follows:
fractioncleaved≈fractionheteroduplex ¼ 1−
Xm
i¼1
p2j ð2Þ
where m is the number of possible sequences, with m-1
mutants and one wt, and pj is the relative amount of
each of the sequences. As explained in more detail and
exemplified in Additional file 1, this calculation shows
that the cleavage fraction would not reach 100 % even
when no wt sequence is present (Additional file 1: Figure
S8). It also shows that for an editing efficiency below
30 %, the original equation (1) is particularly appropriate
(see Additional file 1: Supplemental note) while for high
editing efficiencies it becomes unsuitable.
To test the relevance of this calculation in practice, we
hypothesized that the measured frequency of indels by
Fig. 2 Death ligands induce cell death in various cell types within a few hours. Cell death was measured by observing cell morphology by microscopy. a
Cell death kinetics of A549, HepG2 and HeLa cells using IZsTRAIL and IZsCD95L, with and without co-treatment with 5 to 50 μg/ml cycloheximide (CHX). b
Cell death of LN-18, HT-1080, MDA-MB-231 and MCF10A cells treated for 5 h with IZsCD95L (denoted CD95L) or IZsTRAIL (denoted TRAIL), with or without
5 μg/ml CHX. c HeLa cell death kinetics comparison between IZsCD95L and puromycin. While cell death occurred after 2 h with IZsCD95L, it saturated at
30 h with puromycin. b and c: mean ± s.d. of 3 different fields of view with at least 50 cells each
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the TIDE analysis mirrors the likelihood to obtain a
mutation for a particular gRNA. Therefore, we applied
equation (2) using the frequencies shown in Fig. 3a to
derive the expected cleavage fraction in a T7E1 assay.
Strikingly, the resulting predictions (Fig. 3c, green
striped bars) were in good agreement with the measured
cleavage fractions (Fig. 3c, yellow bars). We also esti-
mated the endonuclease-mediated cleavage depending
on varying amount of wt sequence (Additional file 1:
Figure S9). By this means, we observed that the cleav-
age fraction cannot exceed 70 % to 90 % depending on
the gRNA. Thus, the sensitivity of the Sanger sequen-
cing and the aforementioned limitations of the inter-
pretation of the T7E1 assay might readily explain the
discrepancies in the estimation of the editing efficiency.
Importantly, irrespective of the true editing efficiency,
both approaches confirmed a strong enrichment of
gene-edited cells when using CD95-induced apoptosis
as selection strategy.
Phenotyping of gene knock-out effects after death
receptor-based enrichment
As a proof-of-concept, we used the different HeLa cell
lines for a direct phenotyping of introduced gene
mutations. Specifically, we were interested in the role
of p65, IRF3 and TLR3 in double-stranded (ds)RNA-
induced apoptosis. Some previous studies reported the
requirement of transcriptional activity through p65
and/or IRF3 for this type of death [37–40], while
others showed the possibility of direct cell death
through the formation of the ripoptosome on activated
TLR3 [41, 42]. Notably, this cell death response typic-
ally only occurred in a fraction of the cell population
[41, 42]. To investigate the role of the three genes in
dsRNA-induced death in HeLa cells, we quantified the
death response of edited cells after Poly (I:C) treat-
ment by flow cytometry. Using wt HeLa cells and gfp
gRNA-treated cells as controls, we obtained a cell
death of 26.0 ± 2.0 and 19.8 ± 3.6 %, respectively. Inter-
estingly, in p65, IRF3 and TLR3 gene-edited cell lines,
the cell death response was strongly reduced, ranging
between 3.4 ± 1.8 with TLR3 gRNA-1 and 10.3 ± 1.6 %
with p65 gRNA-3 (Fig. 4). Notably, still 15.7 ± 3.6 % of
non-enriched TLR3 gRNA-1* cells were killed by Poly
(I:C) treatment. Together, this emphasizes that the
three genes are involved in this type of death and that
enrichment of gene-edited cells helps to directly assess
the associated cellular phenotype.
Table 1 Sequence of single guide RNA (gRNA), forward and reverse PCR primers (PCR-fw and PCR-rev), and primers used for sequencing
(p1 and p2)
Gene Type/Name Sequence Genomic location (Assembly Dec. 2013 GRCh38/hg38)
IRF3encoded on (−) strand of genome gRNA-1 GCCACTGGTGCATATGTTCC 19:49663483–49663502 (−)
gRNA-2 CCACTGGTGCATATGTTCCC 19:49663482–49663501 (−)
gRNA-3 ATAAGCCAGACCTGCCAACC 19:49663455–49663474 (−)
PCR-fw TTCTCACCTGGGTATCAGAAGTA 19:49663181–49663203 (+)
PCR-rev TGAGGTTCCTAACTACCGAATTA 19:49664294–49664316 (−)
p1 TGTCTGGCTGGGAAAAGTC 19:49663232–49663250 (+)
p2 CTGTAATCCCAGCACTTTG 19:49663960–49663978 (−)
TLR3encoded on (+) strand of genome gRNA-1 ACATTAGATCTGTCTCATAA 4:186078849–186078868 (+)
gRNA-2 ATTAGGAACTCAGGTTCAGC 4:186078887–186078906 (+)
gRNA-3 GGCTTGTCATCTACAAAATT 4:186078870–186078889 (+)
PCR-fw TGTGTTTGATAAGCCATGTGA 4:186078463–186078483 (+)
PCR-rev GGAGGCTAGAGAGGGAGAAC 4:186079465–186079484 (−)
p1 AATCCTTCCTACAATGG 4:186078618–186078634 (+)
p2 AGGATTGCTGGAAGACAGG 4:186079129–186079147 (−)
p65encoded on (−) strand of genome gRNA-1 TCAATGGCTACACAGGACCA 11:65661815–65661834 (−)
gRNA-2 AGGGACAGTGCGCATCTCCC 11:65661796–65661815 (−)
gRNA-3 AGCTTGTAGGAAAGGACTGC 11:65661737–65661756 (−)
PCR-fw AATGGTTTTCTTCCTCAAACAA 11:65661392–65661413 (+)
PCR-rev CTTAGTTTCACCGCAGGTTCTA 11:65662331–65662352 (−)
p1 GTATCCCCTGGAACTCATC 11:65661487–65661505 (+)
p2 TGTTCCCCCTCATCTTC 11:65662186–65662202 (−)
gfp gRNA AAGGGCGAGGAGCTGTTCAC -
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Fig. 3 (See legend on next page.)
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Comparison of cell enrichment by death receptors versus
puromycin
Finally, we compared the gene editing efficiency in
HeLa, HT-1080 and LN-18 cells when using the death
receptor-based versus the puromycin-based selection
approach. For this, we targeted the gene IRF3 using
gRNA-3 either with the Cas9–2a-CD95ΔDD plasmid
used above, as CD95L was most potent to kill those cell
lines, or with the Cas9–2a-puro plasmid (shown in
Fig. 1a). Two days after transfection with Cas9–2a-
CD95ΔDD, cells were incubated with IZsCD95L for 5 h
or left untreated. HeLa, HT-1080 and LN-18 cells trans-
fected with Cas9–2a-puro were treated for 30 h with 5,
3 and 5 μg/ml puromycin, respectively, or left untreated.
The concentrations were chosen to ensure a complete
killing of the cells (Fig. 2c and S10a). Cells were then
maintained in culture until the density of all treated cells
allowed their characterization, between 7 and 11 days
post-transfection.
As assessed by the TIDE analysis of sequenced PCR
products, we obtained different efficiencies depending
on the cell type and the selection strategy (Fig. 5). For
each condition, the fraction of indels was calculated by
dividing their amount by the amount of wt and indel se-
quences (Fig. 5a). For death receptor-enriched cells, the
fraction of indels in HT-1080 cells was 100 and 94 %, in
LN-18 cells 29 and 25 %, and in HeLa cells 100 and
100 %, respectively, in two biological replicates each. For
puromycin-enriched cells, HT-1080 cells showed 100 %
indels, LN-18 cells 94 and 65 %, and HeLa cells 80 and
73 %. In contrast, in non-enriched transfected cells,
indels were detected only in one replicate of LN-18 cells
transfected with Cas9–2a-puro (2.2 %), in HeLa cells
with Cas9–2a-puro (41 and 39 %), and in HeLa cells
with Cas9–2a-CD95ΔDD (40 and 33 %) (Fig. 5b). As ex-
pected, enriched and transfected control cells (gfp
gRNA) displayed only wt sequences (Fig. 5c). Finally,
Western blotting confirmed the different observed effi-
ciencies at the protein level, with equal efficiencies for
both strategies in HT-1080 cells, a slight advantage for
puromycin-selected LN-18 cells, and better efficiencies
for death receptor-selected HeLa cells (Additional file 1:
Figure S10b). Notably, as in the pilot experiment (Fig. 3),
we found the frequent deletion of 1 and 8 nucleotides as
well as insertion of 1 nucleotide with this gRNA (IRF3
gRNA-3). Remarkably, in each cell line and in each repli-
cate, their relative frequency was similar (Fig. 5d).
Discussion
The CRISPR/Cas9 technology allows for the study of
gene function through targeted DNA modification. In
principle, it permits the investigation of cellular networks
with a greater sensitivity than with RNA interference
approaches where gene expression reduction is only par-
tial. However, this sensitivity can be tempered by the lim-
ited delivery efficiency of Cas9 and the gRNA [3, 6, 15].
Different strategies were employed to increase the per-
centage of Cas9-expressing or gene-edited cells: isolation
of single cells to generate monoclonal cell lines or gener-
ation of polyclonal cells by enriching Cas9-expressing cells
Fig. 4 Poly (I:C)-induced cell death is reduced in cells with impaired
TLR3, IRF3 and p65 expression. 24 h after transfection of 2 μg/ml
Poly (I:C) with DOTAP, fractional cell death was measured by flow
cytometry using propidium iodide. We compared wt Hela cells and
polyclonal HeLa cell lines generated with the nine different gRNAs
targeting TLR3, IRF3 and p65 genes and the control gRNA
targeting GFP. TLR3 gRNA-1 cells denoted with a star (*) were
not treated with IZsCD95L, while ctr. denotes HeLa wt cells
transfected with a non-triphosphate 19-mer RNA control to account
for cell death due to transfection with DOTAP. Shown are means ±
s.e.m. of 3 independent experiments
(See figure on previous page.)
Fig. 3 Editing of IRF3, p65 and TLR3 genes in HeLa cells using the Cas9-T2A-CD95Δ construct and IZsCD95L as selection agent. Three different
gRNAs per gene were tested and a control gRNA targeting GFP was used. Cells denoted as TLR3 gRNA-1* were not treated with IZsCD95L. a Sanger
sequencing results. The frequency of indels in polyclonal cell lines was quantified from chromatograms using the TIDE analysis. Genome extraction,
PCR and sequencing were performed twice. PCR1 was in addition sequenced with a second primer (p2). Mutation = 0 represents wild type sequence.
The non-interpretable fraction (n.i.) relates to the correlation coefficient of the TIDE analysis with R2 = 100 - n.i. b Representative agarose gels from three
T7E1 assays. Genome extraction from polyclonal HeLa cell lines, PCR and T7E1 digest were repeated three times. c Predictions of the cleavage fraction
were obtained by estimating the amount of heteroduplexed DNA by using equation (2) and data from the Sanger sequencing (green-striped).
The cleavage fraction (yellow bars) was quantified from T7E1 assays by: cleaved DNA/(cleaved DNA + non-cleaved DNA). d Purple-striped bars
show the predicted editing efficiency using equation (1) and data from the T7E1 assay. A different estimate of the editing efficiency was obtained by
Sanger sequencing and the TIDE analysis (grey bars)
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through GFP fluorescence or antibiotics like puromycin
[20] or magnetic bead isolation of receptor-overexpressing
cells [24]. In this work, we extended this panel of options
with the death receptor-based Cas9 selection strategy.
Similar to antibiotics-based selection, our new strategy
does not require any transfer of the cells during the selec-
tion process. Moreover, our method can be applied in cell
lines that already stably express resistance genes. Import-
antly, while the selection efficiency matches the one ob-
tained with puromycin, the death receptor-based method
minimizes the time required for the selection. Finally, it
can be used in laboratories with no capacity to sort cells
or to produce viruses. One drawback is the applicability to
cells that are fully death ligand-sensitive. This is for
example not the case for induced pluripotent stem cells
[43], and testing of the effect of the ligand on cells of
interest should be the first step to be performed. However,
the production of the death ligand can be easily accom-
plished in the laboratory, does not require protein purifi-
cation and is inexpensive.
Thus far, the CRISPR/Cas9 technology has been applied
to pooled genomic screens, where upon negative or positive
selection, gene hits are identified by sequencing of the sta-
bly integrated gRNA [7]. We envision a major application
of our death receptor-based enrichment strategy in arrayed
screens, where, as an alternative option to antibiotic-based
enrichment, it should increase the sensitivity of phenotyp-
ing. In this context, cell transfection, selection, washing and
expansion could be implemented in the same plate prior to
phenotyping. Hence, existing pipelines for arrayed RNAi
screens could be easily adapted [14]. Parameters to be opti-
mized would be the cell number to be plated and the time
for their expansion, so that the cell density allows for phe-
notyping. Here, we have exemplarily shown the involve-
ment of three genes in Poly (I:C)-induced cell death in
HeLa cells, and we plan to use this array approach to iden-
tify additional genes involved in this as well as other path-
ways induced by dsRNA. Notably, thanks to the power of
the enrichment approach, optimization of the transfection
efficiency was not required.
In order to quantify the efficiency of gene editing by
the CRISPR/Cas9 method, we employed and compared
the T7E1 assay and the TIDE analysis [35]. Although
both approaches yielded congruent results on the en-
richment of gene editing after death receptor-mediated
cell killing, they generated significantly different outputs
for the editing efficiency. As explained in the results and
in the Additional file 1: Supplemental note, the estimate
of the editing efficiency calculated from an endonuclease
assay result is strongly dependent on the underlying
Fig. 5 Death receptor-based and puromycin-based enrichment of Cas9-expressing cells. In two independent experiments, HT-1080, LN-18 and
HeLa cells were transfected with plasmid Cas9-2A-CD95ΔDD or Cas9-2A-puro encoding gRNA-3 targeting the IRF3 gene or gRNA targeting gfp.
Cell lines were tested against wild type cells for presence of indels in the gene IRF3 using primer IRF3 p1 (Table 1). Indels were detected by Sanger
sequencing and TIDE analysis. a Selection using IZsCD95L or 5 μg/ml puromycin treatment. b No selection. c gfp gRNA cells treated with IZsCD95L or
5 μg/ml puromycin. Mutation= 0 represents wild type sequence. The non-interpretable fraction (n.i.) relates to the correlation coefficient with R2 = 100 - n.i.
d The relative frequency of indels in enriched cells was calculated by dividing their amplitude from panel 5a by the sum of all indels
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assumptions. While equation (1) relies on the postula-
tion that mutated strands cannot anneal with strands
carrying the same mutation due to a hypothetically large
diversity of indels, the more general equation (2) shows
that equation (1) is actually only valid under two condi-
tions: low editing efficiency and/or very large diversity of
indels all exhibiting low probabilities. In this work, we
obtained high editing efficiencies, with mostly few indels
representing the majority of mutations (Additional file 1:
Figure S7). Hence, equation (2) should be more appro-
priate compared to equation (1) traditionally used to
assess genome editing efficiency. Confirming its rele-
vance, the symmetric parabolic shape obtained from this
equation with the most extreme case of one possible
indel (Additional file 1: Figure S8) has been observed in
an in vitro experiment that mimics this situation [44].
Simulation of such situations led to several conclusions
that are of general interest when interpreting the
cleavage fraction (fractioncleaved = cleaved/[cleaved +
noncleaved]) from the T7E1 or Surveyor assay to de-
termine editing efficiency:
1. One cannot reach a 100 % cleavage fraction with the
T7E1 assay, even in perfect technical setups.
2. Due to the parabolic shape of equation (2), within a
certain range, two possible editing efficiencies can be
assigned to one cleavage fraction (Additional file 1:
Figure S8).
3. The maximal cleavage fraction does not correspond
to the maximal editing efficiency.
4. Although equation (2) is universal, its coefficients
depend on the indel pattern, not known a priori.
5. When editing efficiency is high, the sensitivity of the
T7E1 assay to detect changes in this efficiency is
particularly poor. Although this effect can also be
seen for equation (1) for high editing efficiencies, it
becomes even stronger when one takes into account
the limited diversity of indels with equation (2)
(Additional file 1: Figure S8).
6. For a low editing efficiency, the relationship between
cleavage and efficiency is reasonably independent of
the indel pattern, and the T7E1 assay is particularly
sensitive (see Additional file 1: Supplemental note
for details). Therefore, comparison of different gRNAs,
which generate different patterns, should be performed
under conditions with more than 70 % wt sequence.
On top of these theoretical considerations, one should
mention that the T7E1 and Surveyor assays are likely
unable to generate a complete cleavage of duplexes. A
direct comparison of both assays indicated a maximum
of 80 and 60 % cleavage of heteroduplexes with the
T7E1 and Surveyor assays, respectively [44]. In this
work, by taking into account the different indels that
were identified from the TIDE analysis for the distinct
gRNAs used in this study, we observed that the range of
cleaved fraction using the T7E1 assay, between 75 and
90 %, was theoretically compatible with a 100 % editing
efficiency. In practice, however, this means that when
large amounts of cleaved PCR products are observed by
T7E1, a precise estimation of editing efficiency using this
assay cannot be expected.
Overall, the sequencing approach provided not only
information on editing efficiency, but also interesting
information on the type and relative amount of indels.
Since the indel pattern using IRF3 gRNA-3 was repro-
duced in different cell lines and experiments, our data
strengthen the notion that the type of indel is governed
by the choice of the gRNA sequence. Moreover, as IRF3
gRNA-1 and gRNA-2 were only shifted by 1 nucleotide
but showed a very different indel pattern, the cutting
position is likely to have a strong influence on this
pattern. DNA repair studies suggest that this pattern is
driven by the presence of microhomology sequences on
both sides of the cut. Such sequences of 1 to 4 nucleotides
can influence the repair by non-homologous end joining
[45], while larger ones may lead to microhomology-
mediated end joining even if they are further apart from
the cutting site [46–48]. A closer examination of the
gRNA sequences (Additional file 1: Figure S11) allowed to
identify three microhomology domains that may explain
prominent peaks for deletion of 6, 8 and 6 nucleotides for
TLR3 gRNA-2, IRF3 gRNA-3 and p65 gRNA-1, respect-
ively. The use of computer tools that predict indels using
microhomology sequences like the one presented in refer-
ence [48] should therefore help to design gRNAs that
generate interesting indel patterns.
Conclusions
Our work demonstrates the usefulness of death recep-
tors as tool for the selection of Cas9-expressing cells.
Killing non-transfected cells with death ligands can trig-
ger enrichment of gene-edited cells that allows for direct
assessment of gene function. The here presented extension
of the tool panel based on the CRISPR/Cas9 technology
will particularly enhance low- and high-throughput pheno-
typing screening after CRISPR-mediated gene knockdown.
Methods
Cell culture
MDA-MB-231 and HT1080 cells were obtained from
CLS (Eppelheim, Germany). LN-18 cells were a kind gift
from Ana Martin-Villalba. MCF-10A cells were obtained
from ATCC (Manassas, VA, USA). HeLa cells were the
so-called HeLa Kyoto and were obtained from Holger
Erfle. A549 and 293 T cells were kind gifts from Ralf
Bartenschlager and Dirk Grimm, respectively. HeLa,
HT-1080, MDA-MB-231, LN-18, 293 T and A549 cells
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were maintained in Dulbecco’s modified eagle medium
(DMEM, Life Technologies, Darmstadt, Germany) con-
taining 10 % fetal calf serum (Biochrom AG, Berlin,
Germany), penicillin/streptomycin (100 μg/ml each, Life
Technologies). MCF 10A cells were maintained in
DMEM with F12 (Life Technologies), 5 % horse serum
(Biochrom AG), 20 ng/ml EGF (TEBU-Bio, Offenbach,
Germany), 0.5 μg/ml hydrocortisone (Sigma-Aldrich, St.
Louis, Missouri, USA), 10 μg/ml insulin (Sigma-Aldrich)
and penicillin/streptomycin (100 μg/ml each, Invitrogen).
For ligand production, 293 T cells were transfected using
branched polyethylenimine (PEIpro, PolyPlus, Illkirch,
France). In detail, for 20 ml of ligand, 4.5 million cells were
plated in a 15 cm cell culture dish, transfected the next day
with 12 μg of plasmid and washed 24 h later. The super-
natant was collected 48 h after washing, and stored at 4 °C
for several months. The concentration was typically in the
range of 1 μg/ml as estimated by quantitative western blot-
ting (data not shown). X-tremeGENE was used for the
transfection of the Cas9 constructs, while Polyinosinic:-
polycytidylic acid (Poly(I:C)) and 5’ppp-dsRNA control
(Invivogen, San Diego, CA, USA) were transfected with
DOTAP (Carl Roth, Karlsruhe, Germany). Puromycin
was from Life Technologies.
Plasmids
DR4-ΔDD and DR5-ΔDD were amplified from Gateway
full ORF clones from the genomics and proteomics core
facilities of the DKFZ, Heidelberg. CD95-ΔDD was ampli-
fied from the full-length coding sequence of CD95 kindly
provided by Peter Krammer. DR4-ΔDD, DR5-ΔDD and
CD95-ΔDD contain the first 290, 250 and 210 amino acids
of the full-length human DR4, DR5 and CD95, respectively.
The gene coding for puromycin N-acetyl-transferase was
amplified from the Cas9–2a-puro plasmid used in Shalem
et al. [10] (originally Addgene #49535). The Cas9 sequence
is the one derived from Streptococcus pyogenes originally
used in Shalem et al. [10] (Addgene #49535). It is preceded
by a CMV promoter, and followed by a SV40 nuclear
localization sequence, the 2A peptide from Thosea asigna
virus T2A EGRGSLLTCGDVEENPGP, a peptide linker
RSMH and the cDNA of one of the four resistance genes
without the first methionine-encoding triplet. In the Cas9-
T2A-DR5ΔDD-F2A-DR4ΔDD construct, the DR5ΔDD
and DR4ΔDD are separated by the foot-and-mouth disease
virus 2A peptide F2A VKQTLNFDLLKLAGDVESNPGP
preceded by the linker SG and followed by the linker
RSMH. In construct Cas9-T2A-DR5ΔDD-F2A-DR4ΔDD-
P2A-CD95ΔDD, the additional CD95ΔDD is separated
from DR4ΔDD by the porcine teschovirus-1 2A peptide
P2A ATNFSLLKQAGDVEENPGP, and preceded by the
linker GSG and followed by the linker RSMH. The coding
sequence for the guide RNA was cloned on the same plas-
mid and driven by a 7SK promoter. gRNA design was
performed using the ZiFiT Targeter software [49, 50]. All
constructs were cloned based on the pSSV9 vector [51], in
which the entire cassette consisting of the Cas9 and gRNA
expression units was inserted between the two XbaI sites.
IZsCD95L [33], kindly provided by Henning Walczak,
was cloned into pIRES-puro2 (Clontech Laboratories,
Inc., CA, USA), and IZsTRAIL was built from IZsCD95L
in pIRES-puro2. In the following the amino acid se-
quence for IZsCD95L and IZsTRAIL in one-letter code
starting from the N-terminus is given. To allow protein
secretion, we used the N-terminal signal sequence
MGTPHLQGFLLLFPLLLRLHGASAGS in the construct
IZsTRAIL, and the signal sequence MARRLWILSL-
LAVTLTVALAALE in the construct IZsCD95L. In
both constructs, those were followed by the Flag tag
DYKDDDDK and amino acids PSQKSKRRTSSDRMK
QIEDKIEEILSKIYHIENEIARIKKLIGERTR encoding
the isoleucine-zipper domain (PDB entry 1GCM). In
IZsCD95L, the sequence encoding CD95L from amino
acids 117–281 (STSQ…LYKL) was used. In IZsTRAIL,
the linker SGGSSG bridges the IZ domain to the
extracellular receptor binding domain of TRAIL from
amino acids 122–281 (VAAH…FLVG). The sequence of
TRAIL was amplified by PCR from cDNA of NK92-C1
cells, kindly provided by Carsten Watzl.
Western blot
Western blots were performed by lysing cells using ice-
cooled lysis buffer (20 mM Tris/HCl, pH 7.5,
150 mM NaCl, 1 mM phenylmethylsulfonyl fluoride
(Sigma-Aldrich), protease inhibitor cocktail, 1 Triton
X-100 (Serva, Mannheim, Germany), and 10 % gly-
cerol). Lysates were analyzed using SDS-PAGE gels
(Novex NuPAGE 10 % Bis-Tris Protein Gel, Life Tech-
nologies). Proteins were transferred to PVDF membrane
(Millipore, Billerica, MA, USA) using wet blotting. IRF3
was detected using the primary antibody clone D83B9
(Cell Signaling Technology, Danvers, MA, USA). Second-
ary anti-rabbit antibodies were HRP-conjugated (Dianova,
Hamburg, Germany). Detection was performed using the
Pico Chemiluminescent Substrate from Thermo Scientific
(Asheville, NC, USA) and a CCD camera.
Immunofluorescence
CD95, DR4 and DR5 were detected in living cells using
the antibody clones DX2, DJR1 and DJR2–4, respectively,
each labeled with phycoerythrin (PE) (eBioscience Inc,
San Diego, CA, USA). Cells were trypsinized, blocked on
ice with 1 % bovine serum albumin (BSA, Sigma) in PBS,
incubated for 30 min with antibody in blocking buffer on
ice and directly measured by flow cytometry (Beckman
Coulter, Krefeld, Germany).
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Poly (I:C) treatment
75000 cells were seeded into wells of a 24-well plate and
treated one day later by transfection of 2 μg/ml (final
concentration, f.c.) Poly (I:C). 24 h later, dead and living
cells were collected. Cell supernatant, potentially con-
taining living and dead cells, was transferred into empty
wells of a 24-well plate. Remaining cells were washed
once with PBS and trypsinized. PBS and trypsinized cells
were merged with the previously collected cell super-
natant. Sample was incubated with propidium iodide
(solution, 1 μg/ml f.c., Sigma-Aldrich) 10 min before
measurement by flow cytometry (Beckman Coulter).
Editing analysis
Genomic DNA was extracted using the DirectPCR®
Lysis-Regent Cell (Peqlab, Erlangen, Germany) according
to the protocol. PCRs were performed using the Phusion
Flash PCR master mix (Thermo Scientific). T7 endonucle-
ase I was from NEB (Ipswich, MA, USA). Oligonucleotides
were from Eurofins MWG Operon (Ebersberg, Germany),
and Sanger sequencing was performed by GATC Biotech
(Konstanz, Germany).
Microscopy
Cell death was measured by microscopy using transmission
imaging and visual cell morphology identification. Images
were taken on a Leica SP5 confocal microscope (Leica
Microsystems, Mannheim, Germany) or on an Olympus
CKX41 wide-field microscope equipped with an Olympus
PEN Lite CCD camera (Olympus Europa, Hamburg,
Germany). Cell death kinetics were quantified from images
by manually marking the first rounding and shrinkage
event due to cell death. Marks were then automatically
segmented and counted in ImageJ.
Computer simulations
Simulations to predict the T7E1 cleavage fraction from
indel patterns were performed using MATLAB (The
MathWorks GmbH, Ismaning, Germany).
Ethics
No ethics approval was required for use of any of the
cell lines in this study. Cell lines used in this study were
MDA-MB-231, HT1080, LN-18, MCF-10A, HeLa, A549
and 293 T cells and are available from the ATCC
organization (Manassas, VA, USA).
Additional file
Additional file 1: Figure S1. Transient expression of death receptor
mutants in HeLa cells using Cas9-2A constructs was quantified by flow
cytometry. Figure S2. Transient expression of death receptor mutants in
HT-1080 cells using Cas9-2A constructs was quantified by flow cytometry,
as in Figure S2. Figure S3. Transient expression of death receptor mutants
in LN-18 cells using Cas9-2A constructs was quantified by flow cytometry, as in
Figure S2. Figure S4. Transient expression of death receptor mutants in MDA-
MB-231 cells using Cas9-2A constructs was quantified by flow cytometry, as in
Figure S2. Figure S5. Cell death kinetics of MDA-MB-231 using 1 and 3 μg/ml
puromycin (n= 181 and 182 cells) and of LN-18 cells using 3 and 5 μg/ml
puromycin (n= 149 and 118 cells) measured by microscopy. Figure S6. Plots
were generated using the software TIDE (http://tide.nki.nl/) and modified for
clarity. Figure S7. Ranked frequency of indels, normalized to 100% for the total
(upper plot) or for the most frequent indel (lower plot). Figure S8. Estimate of
the cleavage fraction obtained by the T7E1 assay. Figure S9. Estimate
of endonuclease mediated cleavage depending on the amount of wild
type for experimentally observed indel patterns. Figure S10. Death
receptor-based and puromycin-based enrichment of Cas-9 expressing
cells. Figure S11. The TIDE analysis provided information on the insertions
and deletions that are introduced in a specific genomic region targeted by
the gRNAs. Supplemental Note - Editing Efficiency. (PDF 5416 kb)
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